Rosuvastatin Calcium/Nebivolol Hydrochloride

瑞舒伐他汀钙/盐酸奈必洛尔

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRosuvastatin Calcium/Nebivolol Hydrochloride
Drug Alias NameNebivolol/rosuvastatin盐酸奈必洛尔/瑞舒伐他汀钙Nebivolol Hydrochloride/Rosuvastatin CalciumRosuvastatin/nebivololEL-1401
ClassificationSmall molecules
Mechanisms of ActionHMG-CoA reductase inhibitorsBeta-1 adrenergic receptor antagonists
TargetsBeta-1 adrenergic receptorHMG-CoA reductase
Therapy Area/IndicationsHyperlipidemiasHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Nebivolol HydrochlorideRosuvastatin Calcium
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesElyson Pharmaceutical
China Registration ClassN/A

Develop Information

Active CompaniesElyson Pharmaceutical
Inactive CompaniesN/A
Active IndicationsHyperlipidemiasHypertension
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A